These findings suggest that development of stable small molecules that targets hepatocyte TMEM16A or screening an inhibitor that blocks TMEM16A/VAMP3 interaction may be a viable therapeutic strategy for NAFLD treatment. The gene discussed is ANO1; the disease is metabolic dysfunction-associated steatotic liver disease.